Cardiac Surgical Procedures

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
Insulin infusion with a goalPhase 31 trial
Active Trials
NCT00282698Completed400Est. May 2005
CSL Behring
CSL BehringIL - Bradley
1 program
1
Fibrinogen concentratePhase 21 trial
Active Trials
NCT01187225Completed63Est. Nov 2011
XVIVO
XVIVOSweden - Mölndal
1 program
Colloid priming solution for ECC circuitN/A1 trial
Active Trials
NCT04293744TerminatedEst. Oct 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskInsulin infusion with a goal
CSL BehringFibrinogen concentrate
XVIVOColloid priming solution for ECC circuit

Clinical Trials (3)

Total enrollment: 463 patients across 3 trials

NCT00282698Novo NordiskInsulin infusion with a goal

Outcomes With Tight Control of Hyperglycemia in Cardiac Surgery Patients

Start: Jul 2004Est. completion: May 2005400 patients
Phase 3Completed
NCT01187225CSL BehringFibrinogen concentrate

Fibrinogen Concentrate In Children After Cardiac Surgery

Start: Aug 2010Est. completion: Nov 201163 patients
Phase 2Completed
NCT04293744XVIVOColloid priming solution for ECC circuit

Acute Kidney Injury After Cardiac Surgery

Start: Sep 2020Est. completion: Oct 2023
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space